Evidence map›Paper›PMID 42829421›Full record

ReviewJournal of ophthalmic inflammation and infection2026

Current landscape of drug induced retinal vasculitis.

Sivaraman Bala Murugan, Aneena Anna Thomas, Rakshita Deepak Kene, Aditya Rajan, Anup Kelgaonkar, Vedhanayagi Rajesh, Anjana Somanath, Padmamalini Mahendradas, Gokulvasanth Deivasenathipathi, Parthopratim Dutta Majumder

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of ophthalmic inflammation and infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sivaraman Bala MuruganDepartment of Uveitis, Aravind Eye Hospital, Pondicherry, India. drbalamuruganms@gmail.com.
Aneena Anna ThomasDepartment of Uveitis and Ocular Immunology, Narayana Nethralaya, Bengaluru, India.
Rakshita Deepak KeneDepartment of Uvea & Intraocular Inflammations, Sankara Nethralaya, Chennai, India.
Aditya RajanUveitis service, Anant Bajaj Retina Institute, L V Prasad Eye Institute, Bhubaneswar, India.
Anup KelgaonkarUveitis service, Anant Bajaj Retina Institute, L V Prasad Eye Institute, Bhubaneswar, India.
Vedhanayagi RajeshUvea Services, Aravind Eye Hospital, Madurai, India.
Anjana SomanathUvea Services, Aravind Eye Hospital, Madurai, India.
Padmamalini MahendradasDepartment of Uveitis and Ocular Immunology, Narayana Nethralaya, Bengaluru, India.
Gokulvasanth DeivasenathipathiDepartment of Uveitis, Aravind Eye Hospital, Pondicherry, India. gokul30101999@gmail.com.
Parthopratim Dutta MajumderDepartment of Uvea & Intraocular Inflammations, Sankara Nethralaya, Chennai, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug-induced retinal vasculitis (DIRV), a complex diagnostic entity, masquerades as infectious or primary autoimmune diseases. Delineating them is a daunting task. This update aims to consolidate clinical evidence focussing on characteristic "vascular signatures" using advanced multimodal imaging tools. Type III (immune complex-mediated) and Type IV (T-cell-mediated) hypersensitivity pathways were involved in diverse range of drugs causing DRIV. The critical therapeutic strategies are highlighted to prevent permanent ischemic damage. Advances in the recent metagenomic markers are added to aid the clinician from a practical standpoint to aid in preventive and personalised ophthalmic care.

Identifiers

PMID42829421
PMCPMC13634021

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.